January 22, 2020
The Ministry of Health, Labor and Welfare (MHLW) on January 21 ordered label revisions related to adverse reactions for five drugs including Astellas Pharma’s SGLT2 inhibitor Suglat (ipragliflozin) and MSD’s SGLT2/DPP-4 inhibitor combo Sujanu (ipragliflozin + sitagliptin). In a notification...read more